CA3010915C - Methods and formulations for treatment of and/or protection against acute liver failure and other hepatotoxic conditions - Google Patents
Methods and formulations for treatment of and/or protection against acute liver failure and other hepatotoxic conditions Download PDFInfo
- Publication number
- CA3010915C CA3010915C CA3010915A CA3010915A CA3010915C CA 3010915 C CA3010915 C CA 3010915C CA 3010915 A CA3010915 A CA 3010915A CA 3010915 A CA3010915 A CA 3010915A CA 3010915 C CA3010915 C CA 3010915C
- Authority
- CA
- Canada
- Prior art keywords
- active agent
- manganese
- pharmaceutically acceptable
- acceptable salt
- dpdp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
- A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Dispersion Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662277232P | 2016-01-11 | 2016-01-11 | |
| US62/277,232 | 2016-01-11 | ||
| US201662361605P | 2016-07-13 | 2016-07-13 | |
| US62/361,605 | 2016-07-13 | ||
| PCT/IB2017/050115 WO2017122120A1 (en) | 2016-01-11 | 2017-01-10 | Methods and formulations for treatment of and/or protection against acute liver failure and other hepatotoxic conditions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA3010915A1 CA3010915A1 (en) | 2017-07-20 |
| CA3010915C true CA3010915C (en) | 2024-06-04 |
Family
ID=57909814
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3010915A Active CA3010915C (en) | 2016-01-11 | 2017-01-10 | Methods and formulations for treatment of and/or protection against acute liver failure and other hepatotoxic conditions |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US11260060B2 (https=) |
| EP (2) | EP3842040B1 (https=) |
| JP (2) | JP7311267B2 (https=) |
| CN (1) | CN108601757A (https=) |
| AU (1) | AU2017208123B2 (https=) |
| CA (1) | CA3010915C (https=) |
| RU (1) | RU2018128793A (https=) |
| WO (1) | WO2017122120A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2964480A1 (en) | 2014-10-31 | 2016-05-06 | Whole Biome Inc. | Methods and compositions relating to microbial treatment and diagnosis of disorders |
| EP3842040B1 (en) * | 2016-01-11 | 2022-03-09 | Egetis Therapeutics AB | Methods and formulations for treatment of and/or protection against acute liver failure and other hepatotoxic conditions |
| JP2020532515A (ja) | 2017-08-30 | 2020-11-12 | ペンデュラム セラピューティクス， インコーポレイテッド | マイクロバイオーム関連障害の処置のための方法および組成物 |
| RU2693677C1 (ru) * | 2018-10-15 | 2019-07-03 | Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского" (ГБУЗ МО МОНИКИ им. М.Ф. Владимирского) | Способ гемокоррекции при лечении печеночной недостаточности |
| CA3140096A1 (en) * | 2019-05-21 | 2020-11-26 | Pendulum Therapeutics, Inc. | Methods and compositions for treating liver disorders |
| WO2022269026A1 (en) | 2021-06-25 | 2022-12-29 | Forschungsgesellschaft Für Arbeitsphysiologie Und Arbeitsschutz E. V. | Treating acetaminophen overdose |
| WO2024095178A1 (en) | 2022-11-01 | 2024-05-10 | Janssen Pharmaceutica Nv | Thrombopoietin mimetic for use in the treatment of acute liver failure |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6566401B2 (en) | 2001-03-30 | 2003-05-20 | The Board Of Trustees Of The Leland Stanford Junior University | N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity |
| FR2823977B1 (fr) | 2001-04-26 | 2006-12-01 | Univ Rene Descartes | Utilisation du mangafodipir dans le traitement des effets d'un stress oxydatif |
| WO2005017094A2 (en) * | 2003-08-19 | 2005-02-24 | Bioadvantex Pharma Inc. | N-acetyl compositions as adjunct therapy for treatment and prevention of cysteine/glutathione deficiency |
| US20090234011A1 (en) | 2005-04-21 | 2009-09-17 | Goldstein Glenn A | N-acetylcysteine amide (nac amide) for the treatment of diseases and conditions associated with oxidative stress |
| JP2010507572A (ja) * | 2006-10-23 | 2010-03-11 | ザ メンタル ヘルス リサーチ インスティチュート オブ ビクトリア | 併用療法 |
| US20080139654A1 (en) * | 2006-12-09 | 2008-06-12 | Eric Mott Soderling | Acetaminophen compositions having minimized side effects including reduced hepatotoxicity |
| CN105688215A (zh) * | 2009-07-06 | 2016-06-22 | 普莱制药公司 | 利用锰配合物化合物与所述化合物之非锰配合物形式的组合的药物组合物和治疗方法 |
| CN107353313B (zh) * | 2012-01-05 | 2019-04-09 | 普莱制药公司 | 新化学实体钙锰福地吡和其他混合金属配合物、制备方法、组合物以及治疗方法 |
| US20140178358A1 (en) * | 2012-12-21 | 2014-06-26 | The United States of America as represented by the Secretary of Department of Health and Human Servi | Means and Methods to Diagnose Liver Toxicity using Putrescine as Biomarker |
| EP3842040B1 (en) * | 2016-01-11 | 2022-03-09 | Egetis Therapeutics AB | Methods and formulations for treatment of and/or protection against acute liver failure and other hepatotoxic conditions |
-
2017
- 2017-01-10 EP EP21158979.1A patent/EP3842040B1/en active Active
- 2017-01-10 EP EP17701925.4A patent/EP3402475B1/en not_active Not-in-force
- 2017-01-10 CN CN201780006292.1A patent/CN108601757A/zh active Pending
- 2017-01-10 WO PCT/IB2017/050115 patent/WO2017122120A1/en not_active Ceased
- 2017-01-10 US US16/068,626 patent/US11260060B2/en active Active
- 2017-01-10 JP JP2018555315A patent/JP7311267B2/ja active Active
- 2017-01-10 CA CA3010915A patent/CA3010915C/en active Active
- 2017-01-10 AU AU2017208123A patent/AU2017208123B2/en active Active
- 2017-01-10 RU RU2018128793A patent/RU2018128793A/ru unknown
-
2021
- 2021-12-03 JP JP2021197319A patent/JP7374163B2/ja active Active
-
2022
- 2022-01-14 US US17/576,197 patent/US12303516B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US12303516B2 (en) | 2025-05-20 |
| US20190015424A1 (en) | 2019-01-17 |
| JP2019501226A (ja) | 2019-01-17 |
| US11260060B2 (en) | 2022-03-01 |
| RU2018128793A3 (https=) | 2020-05-25 |
| EP3402475A1 (en) | 2018-11-21 |
| CN108601757A (zh) | 2018-09-28 |
| AU2017208123A1 (en) | 2018-07-19 |
| AU2017208123B2 (en) | 2022-04-21 |
| JP7374163B2 (ja) | 2023-11-06 |
| EP3842040A1 (en) | 2021-06-30 |
| EP3402475B1 (en) | 2021-10-20 |
| EP3842040B1 (en) | 2022-03-09 |
| CA3010915A1 (en) | 2017-07-20 |
| JP7311267B2 (ja) | 2023-07-19 |
| WO2017122120A1 (en) | 2017-07-20 |
| JP2022019973A (ja) | 2022-01-27 |
| US20220133739A1 (en) | 2022-05-05 |
| RU2018128793A (ru) | 2020-02-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12303516B2 (en) | Methods and formulations for treatment of and/or protection against acute liver failure and other hepatotoxic conditions | |
| Fishbane | N-acetylcysteine in the prevention of contrast-induced nephropathy | |
| McGregor et al. | Rationale and impact of vitamin C in clinical nutrition | |
| Pinheiro et al. | Gastric S-nitrosothiol formation drives the antihypertensive effects of oral sodium nitrite and nitrate in a rat model of renovascular hypertension | |
| US20050070607A1 (en) | N-acetylcysteine compositions and methods for the treatment and prevention of cysteine/glutathione deficiency in diseases and conditions | |
| JP6591995B2 (ja) | ドーパデカルボキシラーゼ阻害剤組成物 | |
| US20070219268A1 (en) | Anti-cancer activity augmentation compounds and formulations and methods of use thereof | |
| Skinner | Nephrotoxicity—what do we know and what don't we know? | |
| CN103038356A (zh) | 乙酰半胱氨酸组合物及其使用方法 | |
| Doyle et al. | Supraspinal inactivation of mitochondrial superoxide dismutase is a source of peroxynitrite in the development of morphine antinociceptive tolerance | |
| AKARSU et al. | Diagnosis and treatment of iron deficiency anemia in patients with inflammatory bowel disease and gastrointestinal bleeding: iron deficiency anemia working group consensus report | |
| ES2593038T3 (es) | Nuevo tratamiento para la amiloidosis asociada a transtirretina | |
| JP2019501226A5 (https=) | ||
| Yang et al. | 4-Phenylbutyrate benefits traumatic hemorrhagic shock in rats by attenuating oxidative stress, not by attenuating endoplasmic reticulum stress | |
| EP1499342A2 (en) | Therapeutic composition for treatment of cancer by arginine depletion | |
| Gurung et al. | mRNA therapy restores ureagenesis and corrects glutathione metabolism in argininosuccinic aciduria | |
| Iwasa et al. | Usefulness of levocarnitine and/or branched-chain amino acids during invasive treatment for hepatocellular carcinoma | |
| Rahimi et al. | Novel ammonia-lowering agents for hepatic encephalopathy | |
| HK40056482B (en) | Methods and formulations for treatment of and/or protection against acute liver failure and other hepatotoxic conditions | |
| HK40056482A (en) | Methods and formulations for treatment of and/or protection against acute liver failure and other hepatotoxic conditions | |
| Patel et al. | Amlodipine overdose | |
| HK1260784B (en) | Methods and formulations for treatment of and/or protection against acute liver failure and other hepatotoxic conditions | |
| JP2004526792A (ja) | 酸化的侵襲効果を治療するためのマンガフォジピルの使用 | |
| Şahiner et al. | Laboratory changes in older patients using SGLT2 inhibitors | |
| Kobylarz et al. | Antidotes in Clinical Toxicology—Critical Review. Toxics 2023, 11, 723 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20211215 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 8TH ANNIV.) - STANDARD Year of fee payment: 8 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241129 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241129 Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241129 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 9TH ANNIV.) - STANDARD Year of fee payment: 9 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260105 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260105 |